Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Food on Asasantin ER PK/PD
NCT02273492Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 1999
- Primary completion
- Oct 1999
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
Phase 1, randomised, open-label trial of dipyridamole + aspirin in ischemic stroke and Transient Ischemic Attack (TIA) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of dipyridamole in plasma at steady state up to 144 hours, Maximum concentration of dipyridamole in plasma at steady state up to 144 hours and 2 more. Started Aug 1999; status: completed.
02
Drugs
dipyridamole + aspirin
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT02273492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273492.